Skip to main content
    A

    Anika Therapeutics Inc (ANIK)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $12.92
    -0.48 (-3.58%)

    Market Cap: $179.50M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Anika Therapeutics Inc (ANIK) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Anika Therapeutics (ANIK) trades at 18.7x trailing earnings and 1.4x sales. Its P/S of 1.4x is below its 5-year median of 2.3x. Its forward P/E is 13.4x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 39.6% higher over the next year. Its free cash flow yield is 1.3%.

    MultipleValue
    P/E (trailing)18.7x
    Forward P/E13.4x
    Price to sales1.4x
    Price to book1.3x
    EV/EBITDA41.7x
    Price to FCF75.4x
    EV/FCF55.8x
    PEG1.3
    FCF yield1.3%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 64.1% below 3.9x and its P/B is 27.8% below 1.8x.

    MultipleCurrent5-year median10-year median
    P/S1.4x2.3x3.9x
    P/B1.3x1.5x1.8x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 5 of the 10 year ends shown that have a P/E, its P/E ranged from 22.8x in 2016 to 63.7x in 2020. 2020 was the highest of those years.

    Year endPriceP/EP/SP/B
    2025$9.61N/A1.2x1.0x
    2024$16.46N/A2.0x1.6x
    2023$22.66N/A2.8x1.6x
    2022$29.60N/A3.8x1.5x
    2021$35.83N/A3.5x1.8x
    2020$45.2663.7x4.9x2.4x
    2019$51.8525.3x6.4x2.6x
    2018$33.6126.1x4.6x1.8x
    2017$53.9127.4x7.0x3.1x
    2016$48.9622.8x7.0x3.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ANIK

    What is ANIK's forward P/E ratio?

    Anika Therapeutics has a forward P/E ratio of 13.4x.

    Is ANIK stock overvalued?

    GNG's valuation label for ANIK is Undervalued.

    What is ANIK's price to sales ratio?

    Anika Therapeutics has a price to sales ratio of 1.4x.

    What is ANIK's PEG ratio?

    Anika Therapeutics has a PEG ratio of 1.3.